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EFFECTIVENESS OF SHORT-
COURSE QUININE AND SINGLE-
DOSE SULFADOXINE-
PYRIMETHAMINE IN THE 
TREATMENT OF PLASMODIUM 
FA LCIPARUM MALARIA IN 
MPUMALANGA PROVINCE, 
SOUTH AFRICA 
Eugene Athan, David N Diirrh eim, Karen Barnes, Nicros 
M Mngomezulu, Aaron Mabuza, John Govere 
Introduction. Quinine therapy for 7 days remains the mainstay 
for treating hospitalised malaria cases in South Africa. 
However, limited resources, including available beds and 
staff, often result in early discharge of non-severe cases, with 
quinine tablets for outpatient use. The effectiveness of shorter 
course quinine therapy coupled with a long-acting 
antimalarial drug has never been established in Africa, in 
particular in a population without malaria immunity. 
Methods. A study was conducted to evaluate the effectiveness 
of a 3-day course of therapy with quinine sulphate (10 
mg/ kg 8-hourly) followed by a single dose of sulfadoxine-
pyrimethamine (SP) according to weight category, before 
discharge, for 133 hospitalised patients with uncomplicated 
Plasmodium falciparum malaria at Shongwe Hospital, 
Mpumalanga province, between February and July 1998. 
Study endpoints included clinical recovery and 
parasitological cure, including polymerase chain reaction 
(PCR) 42 days after initiating treatment. 
Results. One hundred and thirty of 131 patients (99%) 
successfully followed up for 42 days demonstrated clinical 
and parasitological cure. The remaining patient, who had 
evidence of a recrudescent infection on PCR, was 1 of 61 
patients who w ere still parasitaemic on discharge from 
hospital. 
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Conclusion. The abbreviated course of quinine therapy 
coupled with a single dose ·of SP for the treatment of non-
severe hospitalised cases of P. falciparum malaria, in an area 
with demonstrated low levels of SP resistance, was highly 
effective. This approach has potential benefits, including 
reduced duration of hospitalisation, fewer quinine-associated 
adverse events and protection against the evolution of 
quinine resistance by limiting unsupervised quinine therapy 
in the community. It may, however, be prudent to document a 
negative blood film before discharge from hospital. 
s Afr Med J 2001; 91: 592-594. 
Plasmodium falciparum malaria poses a significant health risk in 
the north-eastern border areas of South Africa. Mpurnalanga 
province's lowveld region, which borders Mozambique in the 
east and Swaziland in the south, experiences seasonal malaria 
in the wet summer months from December to April. The 
population of approximately 850 000 people is consequently 
unlikely to have any immunity against malaria. 
Malaria control in the area, is by a combination of residual 
indoor house spraying with synthetic pyrethroids and early 
detection and treatment of cases at p rimary health care clinics. 
First-line therapy for malaria was changed from chloroquine to 
sulfadoxine-pyrirnethamine (SP) in 1997 after an in vivo study 
found 48.4% resistance (Rl, Rll and Rill) to chloroquine, while 
a subsequent SP baseline in vivo study demonstrated a cure rate 
of 94.5% for uncomplicated cases treated with SP.1 
Patients unable to tolerate oral medication and those deemed 
too unwell for outpatien t care, particularly those with features 
of severe disease, as well as pregnant women and children 
under 2 years of age, are referred to the district hospital, 
Shongwe Hospital, for assessment, therapy and possible 
admission. As the majority of patients seen at the hospital are 
referred from clinics up to 70 krn from the hospital and most 
patients have no access to personal transport, a liberal 
admission policy for malaria patients is adopted at the hospital. 
Admitted cases are treated with quinine therapy for 7 days, at 
the recommended dose, either orally or intravenously.2 
During the peak of the malaria season, Shongwe Hospital 
occupancy rates frequently exceed 250%. This results in 
enormous demands on the limited resources available, with 
severe compromise of patient monitoring and nursing care that 
has contributed towards poor malaria treatment outcomes, 
including fatalities.' On the other hand, early discharge of 
patients on oral quinine therapy may jeopardise the continued 
usefulness of this important drug, as its side-effect profile 
discourages patient adherence. 
This conundrum would be addressed if an abbreviated 
course of therapy was shown to be effective for those patients 
clinically well enough to merit earlier discharge. 
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M ETHODS 
An uncontrolled study was conducted between February and 
July 1998 at Shongwe Hospital, Mpumalanga province, to 
evaluate the effectiveness of a 3-day course of therapy with 
quinine sulphate (10 mg/ kg 8-hourly), by intravenous or oral 
route depending on patient tolerance, followed by a single dose 
of SP (according to weight category) before discharge for 
hospi talised patients with P. falciparum malaria. Study 
endpoints included clinical recovery and parasitological cure, 
demonstrated by temperature clearance, Giemsa-stained thick 
film (GTF) and polymerase chain reaction (PCR) 42 days after 
initiating treatment. Parasite counts were performed at the 
Shongwe Hospital laboratory on Giemsa-stained thin films, 
with quality control performed on all films at the provincial 
entomology and parasitology laboratory in elspruit. PCR for 
P. fa/ciparum was also performed on filter-paper blood spots 
collected on all patients at study enrolment and 42-day follow-
up. 
All non-pregnant adults and children over 2 years of age 
sequentially admitted from the beginning of February wi th an 
episode of P. falciparum malaria documented by rapid malaria 
card test (immunochromatographic) and thin film parasitaemia 
greater than 800 asexual parasites/ fll blood were considered 
for inclusion. Patients with a previous history of sulphonamide 
allergy were excluded. Baseline clinical, haematological and 
biochemical evaluation and daily clinical examination and 
parasite counts were performed while the patient was in 
hospital. 
Patients appearing clinically well enough to be discharged 
after 3 days of quinine therapy, i.e. afebrile, ambulatory and 
where possible with a negative malaria film, were considered 
eligible for study inclusion. Informed consent was acquired . Of 
the 133 patients included, 2 patients were lost to follow-up and 
could not be traced for day 42 evaluation. One hundred and 
thirty-one patients (98%) were therefore successfully followed 
up. 
The Mpumalanga Research and Ethics Committee provided 
ethical clearance for the study. 
R ESULTS 
There were 74 female (56.5%) and 57 male (43.5%) patients 
included in the study. Age was accurately documented for 111 
patients and ranged from 4 to 78 years, with a mean age of 20 
years (median 16 years). Geometric mean parasite counts of the 
131 study participants were no 673/fll ( 25 - 1 162 500) at 
admission, 26 75 / fll (0- 675 000) at 1 day, 3 764/ fll (0 - 7 750) 
at 2 days, and 687 /fll (0 - 45 000) at 3 day after admission. 
Sixty-one patients (47%) were still parasitaemic at discharge 
from hospital. 
At 42-day follow-up, all patients were clinically well and 
only 1 patient (0. %) had malaria parasites demonstrated on 
PCR and blood film examination, with a parasite count of 
1 800/ fll. PCR confirmed a recrudescent infection rather than a 
new infection. 
DISCUSSIO N 
The high cure rate of 98% (130/133), based on intention to 
treat, of 3-day quinine therapy and single-dose SP 
demonstrated in this group of patients hospitalised with non-
severe malaria is very encouraging. A literature review 
revealed three dated studies+-< in other areas that documented 
similarly high cure rates (95 - 100%) using a short course of 
quinine combined with a long-acting antimalarial, either SP or 
mefloquine, in areas with high levels of chloroquine resistance. 
These studies were also conducted in regions affected 
predominantly by seasonal malaria transmission at a time 
when SP or mefloquine were still effective against P. falciparum 
malaria. 
The radical cure of P. falciparum requires therapeutic 
antimalarial levels to be maintained for at least three parasite 
Life cycles, i.e. 6 days. Since the half-life of quinine is only 8 
hours, this cannot be achieved by a short course of quinine 
alone. The effectiveness of short-course quinine therapy 
therefore requires combination with a second longer acting 
drug, such as SP, that is still effective against P. falciparum. 
Increased levels of SP resistance have been reported in other 
part of southern Africa where SP has been used a first-line 
therapy, therefore it is imperative that regular in vivo testing of 
SP resistance is conducted to monitor the continued 
effectiveness of this drug. 
The abbreviated regimen cannot be recommended for 
complica ted malaria cases. In Papua ew Guinea between 3% 
and 10% of children with cerebral malaria treated with short-
course therapy failed treatrnent.7 
The only patient to fail therapy in our study was 1 of 61 
patients who remained parasitaemic at discharge, while none 
of the 70 patients with a negative blood film at discharge failed 
therapy. Although this finding wa not of tati tical ignificance 
(Fisher 's exact x' = 0.466), this may simply reflect the low 
failure rate. A blood film performed at day 3 could identify 
patients possibly at greater risk of recrude cence; in these case 
a longer course of quinine should be con idered . 
Co CLUSIO 
This study indicates the effectivenes of 3 day of quinine 
therapy coupied with a single do e of SP for the treatment of 
non- evere hospitalised cases of P. falciparum malaria, in an area 
with demonstrated low levels of resistance. It may, however, be 
prudent to document a negative blood film before discharge. 
This approach to therapy has va t potential benefits in 
Mpumalanga province and simila r settings, including reduced 
duration of hospitalisation, fewer quinine-associated adverse 
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events and protection against the evolu tion of quinine 
resistance by limiting unsupervised quinine therapy in the 
community. 
The study received financial support from the Mpumalanga 
Department of Health, and the Department of Pharmacology, 
University of Cape Town. 
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SCREENING FOR PRIMARY 
ALDOSTERONISM- NORMAL 
RANGES FOR ALDOSTERONE AND 
RENIN IN THREE SOUTH AFRICAN 
POPULATION GROUPS 
Brian L Rayner, Jonathan E Myers, Lionel H Opie, 
Yvonne A Trinder, James S Davidson 
Objective. To establish normal ranges for plasma 
aldosterone, renin and aldosterone / renin (A/ R) ratio in 
South African normotensives under typical ou tpatient 
conditions, and to estimate the prevalence of primary 
aldosteronism (PA) among hypertensives in primary care 
settings. 
Design and methods. One hundred and thirty-six 
normotensive subjects and 154 sex- and age-matched 
hypertensives at three primary care clinics had 
measurements of blood pressure, plasma creatinine, 
K+, aldosterone, plasma renin activity, and spot urine for 
urinary Na• I creatinine ratio. Medication was not 
withdrawn before testing. 
Results. Mean plasma renin activity in black normotensive 
subjects (0.95 ± 1.25 ng/ ml / h, mean± standard deviation 
(SD)) was significantly lower than in white (2.09 ± 1.12 
ng/ ml / h; P < 0.0001) and coloured (1.81 ± 1.86 ng/ ml/ h, 
P = 0.013) normotensives. Mean plasma aldosterone in 
black normotensives (306 ± 147 pmol/ 1) was also 
significantly lower than in white (506 ± 324 pmol/1, 
P = 0.0002) and coloured (418 ± 304 pmol/1, P = 0.0148) 
normotensives. In hypertensives, there were no significant 
diHerences in renin or aldosterone levels between the three 
population groups. Urinary Na• I creatinine ratios, an index 
of Na• intake, were not significantly different in the three 
population groups. None of the normotensives had an A / R 
ratio::?: 1 000 plus aldosterone::?: 750, while 7.1% of 
hypertensives exceeded these levels, suggesting that they 
are appropriate criteria for screening for PA. 
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